These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30797713)

  • 41. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 44. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
    Vang R; Shih IeM; Kurman RJ
    Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage.
    Wang Y; Wu R; Cho KR; Thomas DG; Gossner G; Liu JR; Giordano TJ; Shedden KA; Misek DE; Lubman DM
    J Proteome Res; 2009 Mar; 8(3):1452-63. PubMed ID: 19159301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
    Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
    Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
    Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
    Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HMGA2 and high-grade serous ovarian carcinoma.
    Wu J; Wei JJ
    J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
    Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
    Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-grade serous ovarian cancer: State of the science.
    Slomovitz B; Gourley C; Carey MS; Malpica A; Shih IM; Huntsman D; Fader AN; Grisham RN; Schlumbrecht M; Sun CC; Ludemann J; Cooney GA; Coleman R; Sood AK; Mahdi H; Wong KK; Covens A; O'Malley DM; Lecuru F; Cobb LP; Caputo TA; May T; Huang M; Siemon J; Fernández ML; Ray-Coquard I; Gershenson DM
    Gynecol Oncol; 2020 Mar; 156(3):715-725. PubMed ID: 31969252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overexpression of tyrosine kinase receptor B promotes metastasis of ovarian serous adenocarcinoma by lymphangiogenesis.
    Zheng W; Dai Q; Tao P; Sun A; Wang Y; Bao L; Zhang G
    Tumori; 2011; 97(6):756-61. PubMed ID: 22322843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
    BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
    Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
    Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
    Wu W; Wang Q; Yin F; Yang Z; Zhang W; Gabra H; Li L
    Int J Oncol; 2016 Oct; 49(4):1651-65. PubMed ID: 27511453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.
    King ER; Tung CS; Tsang YT; Zu Z; Lok GT; Deavers MT; Malpica A; Wolf JK; Lu KH; Birrer MJ; Mok SC; Gershenson DM; Wong KK
    Am J Surg Pathol; 2011 Jun; 35(6):904-12. PubMed ID: 21451362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A case of ovarian serous adenocarcinoma suggestive of transformation to an AFP-producing tumor during chemotherapy.
    Kataoka A; Nishida T; Sugiyama T; Yakushiji M
    J Obstet Gynaecol (Tokyo 1995); 1995 Oct; 21(5):451-9. PubMed ID: 8542468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells.
    Cheng JC; Auersperg N; Leung PC
    PLoS One; 2012; 7(8):e42436. PubMed ID: 22905131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.